Development of a preventive vaccine against BK virus in transplanted patients
The majority of individuals (80% of the population) have been infected with polyomavirus BK (BKV), but are asymptomatic or have only endured mild symptoms. The virus then resides in the kidneys where it persists in a dormant state for the life of the individual. The virus can, however, become reactivated in the case of deep immunosuppression, most often occurring as a result of kidney transplantation. When this happens, it causes a disease called BK virus nephropathy (BKVN) in 20 to 40% of renal transplanted patients, which causes the loss of the transplant in up to 60% of affected patients. Therefore, potent preventive strategies against BKV, such as vaccination, are urgently needed. By evaluating anti-BKV immune cell responses and identifying BKV protective immune cellular components, we will reveal targets suitable for the development of a vaccine for patients on the kidney transplant waiting list, ultimately allowing them to fight BKV infection after kidney transplantation.
Voir la description complète du projetRéjean Lapointe
Merck Canada Inc (Kirkland, QC);Institut du cancer de Montréal
Life Sciences
Manufacturing; Professional, scientific and technical services
Université de Montréal
Accelerate